Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since March 28, 2022, six healthy volunteers have been administered the novel antimicrobial, which is based on a naturally occuring mechanism of action (MoA) leading […]
continue readingOmnix Medical Wins €10.8M in EIC Accelerator Funding
Novel class of anti-infectives fighting hospital-associated infections and multi-drug resistant bacteria Lead program OMN6 to be advanced to proof-of-concept in humans Antonius Schuh appointed as Chairman of the Board of Directors Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under […]
continue reading